InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (1 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
1
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Fried Robert N, Chief Executive Officer. Officer active across 2 companies, notably Niagen Bioscience, Inc.. Aggregated, 8 filings have been recorded. Split: 4 buys · 1 sell. Total volume traded: €215k. History available since 13 May 2021. The latest transaction was filed on 30 June 2026 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Fried Robert N
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations8 total
1,106 shares@ US$2.710.0011% mcap0.9% of flowCommon StockSEC:0001417952-26-000002:0
20,000 shares@ US$2.610.0088% mcap50.0% of flowCommon StockSEC:0001417952-26-000001:0
66,667 shares@ US$3.3069.2% of flowCommon StockSEC:0001628280-25-017223:0
7,000 shares@ US$1.423.4% of flowCommon StockSEC:0001628280-23-020508:0
Canonical exit: 29 Aug 2023 (T+90)
80,000 shares@ US$1.2537.6% of flowCommon StockSEC:0001628280-22-025915:0
Canonical exit: 29 Dec 2022 (T+90)
25,000 shares@ US$2.1630.9% of flowCommon StockSEC:0001628280-22-006443:0
Canonical exit: 14 Jun 2022 (T+90)
10,000 shares@ US$6.6525.6% of flowCommon StockSEC:0001415889-21-002499:0
Canonical exit: 11 Aug 2021 (T+90)
5,063 sharesCommon StockSEC:0001415889-16-004790:0
8 of 8 declarations
About Fried Robert N
Robert N. Fried is the Chief Executive Officer of Niagen Bioscience, Inc. and ChromaDex Corp. He leads these companies with a vision focused on innovation and growth.
